Back to today’s briefing

Story perspectives

Eli Lilly Hits $1 Trillion, Fueled by Weight-Loss Drug

11/21/2025

31 7 Full Breakdown

Summary

Story summary

Eli Lilly reached a $1 trillion market value on November 21, 2025, becoming the first healthcare company to join this group, aided by Zepbound, Mounjaro, and the anticipated orforglipron.
The rise is driven by its weight-loss drug Zepbound and diabetes treatment Mounjaro.
Mounjaro generated $6.52 billion in the third quarter.
Zepbound sales rose 184%.
Analysts expect the weight-loss drug market to exceed $150 billion by the early 2030s.

1 of 1

Story summary

Eli Lilly reached a $1 trillion market value on November 21, 2025, becoming the first healthcare company to join this group, aided by Zepbound, Mounjaro, and the anticipated orforglipron.
The rise is driven by its weight-loss drug Zepbound and diabetes treatment Mounjaro.
Mounjaro generated $6.52 billion in the third quarter.
Zepbound sales rose 184%.
Analysts expect the weight-loss drug market to exceed $150 billion by the early 2030s.